Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

Mahmood, S Tariq; Agresta, Samuel; Vigil, Carlos E; Zhao, Xiuhua; Han, Gang; D'Amato, Gina; Calitri, Ciara E; Dean, Michelle; Garrett, Christopher; Schell, Michael J; Antonia, Scott; Chiappori, Alberto

Mahmood, S Tariq; Agresta, Samuel; Vigil, Carlos E; Zhao, Xiuhua; Han, Gang; D'Amato, Gina; Calitri, Ciara E; Dean, Michelle; Garrett, Christopher; Schell, Michael J; Antonia, Scott; Chiappori, Alberto.

Affiliation

Mahmood ST; Sarcoma Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Int J Cancer ; 129(8): 1963-9, 2011 Oct 15.

Article in En | MEDLINE | ID: mdl-21154746

Subject(s)

Indoles/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Pyrroles/therapeutic use; Sarcoma/drug therapy; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous/drug therapy; Humans; Indoles/adverse effects; Leiomyosarcoma/drug therapy; Liposarcoma/drug therapy; Male; Neoplasm Metastasis; Protein Kinase Inhibitors/adverse effects; Pyrroles/adverse effects; Recurrence; Retreatment; Sarcoma/pathology; Sunitinib; Survival Rate

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrroles / Sarcoma / Protein Kinase Inhibitors / Indoles Limits: Female / Humans / Male Language: En Journal: Int J Cancer Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google